American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients.
Adam CukerEric K TsengRobby NieuwlaatPantep AngchaisuksiriClifton BlairKathryn DaneMaria T DeSanchoDavid DiuguidDaniel O GriffinSusan R KahnFrederikus Albertus KlokAlfred Ian LeeIgnacio NeumannAshok PaiMarc RighiniKristen M SanfilippoDeborah M SiegalMike SkaraDeirdra R TerrellKamshad TouriElie A AklReyad Al JabiriYazan Al JabiriAngela M BarbaraAntonio BognanniMary Ellene BoulosRomina Brignardello-PetersenRana CharideLuis Enrique Colunga LozanoKarin Lee DearnessAndrea J DarziHeba HusseinSamer G KaramRazan MansourGian Paolo MorganoRami Z MorsiGiovanna Muti-SchünemannMenatalla K NadimBinu A PhilipYuan QiuYetiani Roldan BenitezAdrienne StevensKarla SoloWojtek WierciochReem A MustafaHolger J SchünemannPublished in: Blood advances (2022)
This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.
Keyphrases
- venous thromboembolism
- atrial fibrillation
- end stage renal disease
- randomized controlled trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- liver failure
- high intensity
- respiratory failure
- clinical practice
- systematic review
- clinical trial
- drug induced
- intensive care unit
- extracorporeal membrane oxygenation
- patient reported
- mechanical ventilation